Peptides for Sleep: DSIP, Epitalon and Pinealon Against the Evidence

Do peptides work for sleep?

Legal status first. DSIP (delta sleep-inducing peptide, now officially named emideltide), Epitalon and Pinealon are not approved drugs in the US, the UK, the EU or Australia. In the US, pharmacies can't legally make them either. The July 2026 panel votes were only advice, FDA scientists opposed every one, and nothing changes until the FDA finishes a new rule, as our FDA status tracker explains. Products sold 'for research' are unapproved drugs. What follows checks the sleep evidence for these three peptides against how sleep works, and against the drugs that did get approved.

How approved sleep drugs compare

For a yardstick, the FDA approved daridorexant (Quviviq) on January 7, 2022 for trouble falling or staying asleep. It was tested in 1,854 patients at more than 160 sites. It joined suvorexant and lemborexant, two drugs that block the brain's wake signal, orexin. The FDA's 2022 novel approvals list records it. Those drugs reached the market with sleep measured in a sleep lab, results repeated across studies, in the people they were meant for. The American Academy of Sleep Medicine's guideline, which the FDA quoted in both peptide reviews, does not mention DSIP or Epitalon. It puts talk therapy for insomnia (CBT-I) ahead of any drug. Against that standard, the three peptides here have four small drip studies from before 1993 that disagree, one lab's melatonin marker and no proper insomnia study.

What did the DSIP human trials find?

DSIP was pulled from rabbit blood in Basel in 1977 as a possible sleep chemical. Schneider-Helmert and Schoenenberger gave 6 middle-aged people with long-term insomnia a single 25 nmol/kg drip. They reported longer sleep with fewer wake-ups (Experientia, 1981). In 6 healthy volunteers dosed in the morning, sleep in the next 130 minutes rose 59 percent compared with a dummy drip (Int J Clin Pharmacol Ther Toxicol, 1981).

The follow-ups did not hold up. Monti and colleagues gave people with long-term insomnia the same 25 nmol/kg drip, compared against a dummy drip, with nobody knowing who got which. Wake-ups, time to fall asleep and time awake all fell on DSIP. But 'no significant differences were found in comparison to baseline or to double-blind placebo nights'. The one clear difference, in light sleep, was already there before treatment (Int J Clin Pharmacol Res, 1987). Bes and colleagues put 16 people with long-term insomnia into matched pairs over five nights. Sleep was more efficient and came faster on DSIP. Then they wrote in their own summary that the effects were weak and partly due to a change in the dummy group (Neuropsychobiology, 1992). In 2006, a review in the Journal of Neurochemistry called DSIP 'a still unresolved riddle'. It noted that no gene, parent protein or receptor for DSIP has ever been found, and that the sleep idea 'is extremely poorly documented and still weak' (Kovalzon and Strekalova).

Why did the FDA committee vote against DSIP and for Epitalon?

The FDA's DSIP staff paper, dated May 11, 2026, is the most thorough independent reading of these studies. On whether it works: there was no study of shots under the skin at all, the drip results were 'inconclusive and at best preliminary', and the positive studies mostly compared people with themselves instead of with a separate dummy group. On safety: the FDA's side-effect database had zero reports through March 2024, and the drip studies recorded no serious side effects. A 1984 study of 107 people coming off alcohol or opiates noted short-lived sweating, headache, nausea and dizziness in nine, and low blood pressure at the first shot in two. STAT quoted a panel member who voted yes on other peptides. They said the panel was not being asked to judge dose, whether it works and safety in the usual way. That tells you how much weight to give the 7 to 4 Epitalon vote.

The Epitalon staff paper is shorter on evidence from people, because there is less of it. The request to list it cited one paper that mentions use in people. The FDA's own search 'did not retrieve publications discussing efficacy' in insomnia. The panel voted for it anyway. Under the law, that still means nothing until the FDA writes a rule.

What growth hormone secretagogues do to slow-wave sleep

This is the research that 'sleep peptide' ads borrow from without saying so. Deep sleep and the night-time burst of growth hormone happen at the same time. Axel Steiger's group in Munich gave 7 healthy men GHRH into the vein at 22:00, 23:00, 24:00 and 01:00. The share of the night in deep sleep rose from 14.0 to 20.2 percent, growth hormone went up and the stress hormone cortisol went down (Neuroendocrinology, 1992). The same group tested ghrelin, the body's own hunger hormone. It works on the same receptor as ipamorelin, the GHRPs and MK-677. Four 50 microgram shots raised deep sleep across the night and deep brain waves in the second half. They also cut dream (REM) sleep in the middle of the night and raised cortisol early (Am J Physiol, 2003). Copinschi's study gave 8 young adults MK-677 at 5 and 25 mg for 7 days, and 6 older adults 14-day courses, with each person also getting a dummy pill. At the high dose, the young group got roughly 50 percent more of the deepest sleep and over 20 percent more dream sleep (Neuroendocrinology, 1997).

What does Khavinson's melatonin data show, and what is its limitation?

The typical paper is a 2007 report in Advances in Gerontology. It says night-time and average melatonin fall in older people, and that epithalamin and Epitalon 'recover night release of endogenous melatonin' in those with a weak pineal gland (Khavinson group, 2007). The same paper reports the same pattern in old monkeys. Bringing back melatonin is interesting, but it is a blood marker, not sleep. Low melatonin has not been reliably linked to insomnia in older people, a point the FDA's Epitalon review makes. So even if the finding held up, it would not show that Epitalon treats insomnia. Pinealon, a small three-building-block peptide (Glu-Asp-Arg) from the same school, has small Russian reports in people but no sleep study in people. It has animal studies on protecting the brain. For sleep, it has no evidence.

The bottom line

DSIP is a 49-year-old idea with no receptor, no parent protein and no steady effect in people, and in July 2026 the FDA panel agreed by one vote. Epitalon's melatonin story comes from one source. Pinealon has nothing for sleep. The peptides that do change sleep stages in careful studies are the growth hormone boosters. They come with costs to blood sugar, and they were never tested in insomnia. As of September 2026, the evidence for 'peptides for sleep' is small studies in people at best, and none of it is approved.